关于第四届董事会第十三次会议相关事项的独立意见 江苏苏利精细化工股份有限公司独立董事 根据中国证监会《上市公司独立董事规则》、《江苏苏利精细化工股份有限公司章 程》(以下简称"《公司章程》")、《江苏苏利精细化工股份有限公司独立董事制度》 等有关规定,我们作为江苏苏利精细化工股份有限公司(以下简称"公司")的独立董 事,认真审阅了公司第四届董事会第十三次会议相关议案,基于独立判断,发表独立意 见如下: 孙 涛: 崔咪芬: 花荣军: つった 3年 8月20日 《公司 2023 年半年度募集资金存放与实际使用情况的专项报告》内容真实、准确、 完整,不存在虚假记载、误导性陈述和重大遗漏,客观地反映了 2023年半年度公司募集 资金存放与实际使用情况,符合中国证券监督管理委员会、上海证券交易所关于上市公 司募集资金存放与使用的相关规定,不存在违规使用募集资金的行为,不存在改变或变 相改变募集资金投向和损害股东利益的情况。 二、对《关于会计政策变更的议案》的独立意见 公司根据财政部发布的《企业会计准则解释第16号》规定,对公司相关会计政策 进行调整,符合财政部、中国证监会、上海证券交易所的相关规定,本次变更对公司财 务 ...

| 证券代码：603585 | 证券简称：苏利股份 | 公告编号：2023-056 | | --- | --- | --- | | 转债代码：113640 | 转债简称：苏利转债 | | 江苏苏利精细化工股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （二）审议程序 2023 年 8 月 28 日，公司第四届董事会第十三次会议审议通过了《关于会计政策变 更的议案》，本议案无需提交股东大会审议。 二、本次会计政策变更的具体情况 （一）变更日期 公司将按照《企业会计准则解释第 16 号》的规定选择于 2023 年 1 月 1 日起执行。 本次会计政策变更是根据中华人民共和国财政部（以下简称"财政部"）会计司发 布的最新企业会计准则及相关通知的要求进行的相应变更，无需提交股东大会审议，修 订后的会计政策符合财政部、中国证监会和上海证券交易所等相关规定，能够客观、公 允地反映江苏苏利精细化工股份有限公司（以下简称"公司"）的财务状况和经营成果， 不会对公司当期损益、财务状况及 ...

| 证券代码：603585 | 证券简称：苏利股份 | 公告编号：2023-055 | | --- | --- | --- | | 转债代码：113640 | 转债简称：苏利转债 | | 江苏苏利精细化工股份有限公司 2023 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第十八号-化工》的要求， 江苏苏利精细化工股份有限公司（以下简称"公司"）现将 2023 年半年度主要 经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量 | 销量 | 营业收入 | | --- | --- | --- | --- | | | （吨） | （吨） | （万元） | | 农药及农药中间体 | 12,080.51 | 11,497.27 | 62,465.89 | | 阻燃剂及阻燃剂中 间体 | 5,381.85 | 6,033.09 | 25,049.96 | 二、主要产品的价格变动情况（不含税） | 主要产品 | 平均售价 | 上年同 ...

| 证券代码：603585 | 证券简称：苏利股份 公告编号：2023-031 | | --- | --- | | 转债代码：113640 | 转债简称：苏利转债 | 江苏苏利精细化工股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 6 月 1 日(星期四)下午 15:00-16:30 本次投资者说明会以视频录制及网络文字互动的形式召开，公司将针对 2022 年年度及 2023 年第一季度的经营成果及财务指标的具体情况与投资者进行 会议召开地点：上海证券交易所上证路演中心(网址：http://roadshow.ssein fo.com/) 会议召开方式：视频录制及网络文字互动 互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 投资者可于 2023 年 5 月 30 日（星期二）16:00 前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥552,072,654.56, representing a decrease of 30.53% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥22,139,452.33, down 77.45% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥22,179,166.14, a decrease of 77.13% compared to the previous year[5]. - Basic earnings per share were ¥0.12, down 78.18% compared to the same period last year[5]. - Net profit for Q1 2023 was CNY 19.51 million, a decline of 84.4% from CNY 125.28 million in Q1 2022[20]. - Basic earnings per share for Q1 2023 were CNY 0.12, down from CNY 0.55 in Q1 2022[21]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥83,284,707.33, up 1,151.67% year-on-year[5]. - The company received increased export tax rebates, contributing to the rise in net cash flow from operating activities[6]. - The company's cash inflow from operating activities for Q1 2023 was not detailed in the provided documents[22]. - In Q1 2023, the cash inflow from operating activities totaled approximately $571.85 million, a decrease of 9.6% compared to $632.37 million in Q1 2022[24]. - The net cash flow from operating activities increased significantly to $83.28 million, compared to only $6.65 million in the same period last year, marking a substantial improvement[24]. - Cash outflow for purchasing goods and services was approximately $358.00 million, down 28.5% from $502.07 million in Q1 2022[24]. - The company reported a net cash outflow from investing activities of approximately -$136.75 million, an improvement from -$343.13 million in Q1 2022[25]. - Cash inflow from financing activities was approximately $48.37 million, a significant decrease from $1.01 billion in Q1 2022[25]. - The net cash flow from financing activities was $38.58 million, down from $945.90 million in the previous year[25]. - The ending cash and cash equivalents balance was approximately $1.70 billion, compared to $1.59 billion at the end of Q1 2022[25]. - The company received tax refunds amounting to approximately $30.36 million, an increase from $16.99 million in Q1 2022[24]. - The total cash outflow for operating activities was approximately $488.56 million, a decrease from $625.72 million in the same quarter last year[24]. - The company experienced a negative impact of approximately -$390,890 from exchange rate fluctuations on cash and cash equivalents[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,265,534,097.78, a decrease of 0.92% from the end of the previous year[5]. - The company's current assets totaled CNY 3,022,631,384.16, down from CNY 3,181,404,276.54, indicating a decrease of about 4.98% year-over-year[15]. - Cash and cash equivalents were reported at CNY 1,854,393,574.82, a decrease from CNY 1,924,266,642.91, representing a decline of approximately 3.63%[14]. - Accounts receivable decreased to CNY 275,807,562.61 from CNY 350,461,210.94, marking a reduction of about 21.34%[14]. - Inventory levels were reported at CNY 338,529,900.21, down from CNY 351,917,979.87, reflecting a decrease of approximately 3.79%[15]. - The company's long-term equity investments stood at CNY 219,625,070.97, slightly down from CNY 220,209,788.04, indicating a decrease of about 0.26%[15]. - Fixed assets decreased to CNY 839,153,644.10 from CNY 861,040,897.26, representing a decline of approximately 2.54%[15]. - The company's total liabilities decreased to CNY 1.91 billion in Q1 2023 from CNY 1.97 billion in Q1 2022, a reduction of 3.5%[17]. - The total equity increased to CNY 3.36 billion in Q1 2023 from CNY 3.34 billion in Q1 2022, reflecting a growth of 0.3%[17]. - The total current liabilities were not specified, but short-term borrowings decreased significantly from CNY 13,130,896.65 to CNY 4,935,784.06, a reduction of about 62.47%[15]. Market and Operational Insights - The decline in revenue was primarily due to decreased demand in the industry and a drop in both sales prices and quantities of major products[6]. - The company experienced a significant increase in sales expenses by 35.29% as it actively expanded into domestic and international markets[9]. - The report indicates that there are no significant new strategies or product developments mentioned for the upcoming quarters[14]. - The company plans to focus on market expansion and new product development in the upcoming quarters[22]. - Research and development expenses for Q1 2023 were CNY 31.37 million, slightly down from CNY 32.08 million in Q1 2022[19]. - The company reported an investment loss of CNY 277,693.54 in Q1 2023, compared to a gain of CNY 1.14 million in Q1 2022[20]. - The company reported a total of 72,000,000 shares held by its largest shareholder, accounting for 40% of the total shares[12].

Financial Performance - The company's operating revenue for 2022 was CNY 3,150,170,752.32, representing a 34.16% increase compared to CNY 2,347,993,708.64 in 2021[22]. - The net profit attributable to shareholders for 2022 was CNY 315,311,882.85, a 30.60% increase from CNY 241,432,485.47 in 2021[22]. - The net profit after deducting non-recurring gains and losses was CNY 311,642,772.14, reflecting a 29.45% increase from CNY 240,739,183.90 in 2021[22]. - The cash flow from operating activities for 2022 was CNY 519,443,185.81, which is a significant increase of 79.93% compared to CNY 288,695,478.03 in 2021[22]. - Total assets at the end of 2022 reached CNY 5,314,462,822.42, marking a 37.16% increase from CNY 3,874,747,210.35 at the end of 2021[23]. - The net assets attributable to shareholders increased to CNY 2,616,497,212.89, an 18.52% rise from CNY 2,207,607,292.68 in 2021[22]. - Basic earnings per share increased by 30.60% to CNY 1.75 in 2022 compared to CNY 1.34 in 2021[24]. - Diluted earnings per share rose by 11.19% to CNY 1.49 in 2022 from CNY 1.34 in 2021[24]. - The weighted average return on equity increased by 1.41 percentage points to 12.78% in 2022, up from 11.37% in 2021[24]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 5.50 per 10 shares (including tax) for the 2022 fiscal year[6]. - The company's net profit attributable to ordinary shareholders for the reporting period was approximately 315.31 million RMB, with a dividend payout ratio of 31.40%[173]. - The company has established a three-year dividend return plan (2021-2023) to enhance transparency and sustainability in profit distribution[168]. - The company has implemented a cash dividend policy, stating that cash dividends should not be less than 20% of the distributable profits for the year[164]. - The company plans to prioritize cash dividends, with a minimum of 80% for mature stages without major capital expenditures[164]. Operational Efficiency and Growth - The company achieved a consolidated revenue of 3.15 billion CNY, representing a year-on-year growth of 34.16%, and a net profit attributable to shareholders of 315 million CNY, up 30.60% year-on-year, indicating double growth in both revenue and net profit[35]. - The cash flow from operating activities improved due to growth in sales and profits, reflecting the company's operational efficiency[53]. - The company reported a significant increase in research and development expenses, attributed to enhanced investment in R&D and increased personnel and material costs[53]. - The company has established long-term strategic partnerships with leading clients in the industry, ensuring stable demand for its products[44]. - The company is focused on expanding its agricultural product supply chain and enhancing its operational capabilities in the chemical industry[73]. Market and Product Development - The sales volume of the active ingredient pyraclostrobin significantly increased due to deeper cooperation with strategic customers and a gradual recovery in downstream demand[36]. - The company is exploring the production of different grades of brominated polystyrene to meet diverse market demands, which is expected to enhance profitability as production capacity is gradually released[36]. - The company is focusing on the development of key materials and additives for high-quality chemical fiber, including flame retardants and catalysts, in line with national industrial development plans[41]. - The company is actively developing new, environmentally friendly flame retardants to meet the growing demand in various industries, including the automotive sector[89]. - The company is positioned to benefit from the new opportunities arising from the 5G infrastructure, which requires flame retardant materials for high-frequency PCB circuit boards and optical fibers[85]. Environmental Compliance and Sustainability - The company invested approximately 90.28 million yuan in environmental protection during the reporting period[178]. - The company is committed to environmental compliance and has established a framework for monitoring and reporting emissions[182]. - The company has implemented measures to ensure that emissions of key pollutants such as ammonia nitrogen and total phosphorus remain within regulatory limits[182]. - The company has established a comprehensive waste management system for both hazardous and general solid waste[198]. - The company has implemented new strategies for environmental compliance, including maintaining discharge standards for various pollutants[185]. Corporate Governance - The company has implemented a robust corporate governance structure, ensuring compliance with legal requirements and protecting shareholder rights[133]. - The company emphasizes strict compliance with legal and regulatory requirements for information disclosure, ensuring timely and accurate communication with shareholders[135]. - The company has established specialized committees, including the audit committee and the strategic committee, with specific members assigned[151]. - The company has a diverse board of directors, with members holding various positions and responsibilities[137]. - The company maintains a commitment to transparency and equal opportunity for all shareholders[135]. Research and Development - Research and development expenses increased by 22.34% to CNY 138.23 million, reflecting the company's commitment to innovation[51]. - The company obtained a total of 10 invention patents and 14 utility model patents during the reporting period, reflecting its commitment to R&D innovation[91]. - The company continues to enhance its R&D capabilities through partnerships with leading research institutions, focusing on new product development in pesticides and flame retardants[91]. - The company has a strategic focus on technology innovation, rewarding teams and individuals for advancements in product development and process improvements[160]. - The company employed 293 R&D personnel, which represents 21.58% of the total workforce[64].

江苏苏利精细化工股份有限公司 2022 年第三季度报告 证券代码：603585 证券简称：苏利股份 转债代码：113640 转债简称：苏利转债 江苏苏利精细化工股份有限公司 2022 年第三季度报告 一、 主要财务数据 (一)主要会计数据和财务指标 | | | | | 单位：元 币种：人民币 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期 比上年同 | | 年初至报告期 末比上年同期 | | | | 期增减变 | 年初至报告期末 | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 791,344,650.44 | 31.52 | 2,434,674,002.42 | 54.49 | | 归属于上市公司股东的 | 65,994,290.39 | 55.80 | 265,109,611.69 | 90.35 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 65,872,886.68 | 64.25 | 262,322,701.49 | 96.58 | | 利润 | | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2022 reached CNY 1,643,329,351.98, representing a 68.68% increase compared to CNY 974,211,271.52 in the same period last year[20]. - Net profit attributable to shareholders was CNY 199,115,321.30, up 105.44% from CNY 96,919,247.98 year-on-year[20]. - The net cash flow from operating activities was CNY 236,856,236.71, an increase of 104.69% compared to CNY 115,714,872.55 in the previous year[20]. - Basic earnings per share for the first half of 2022 were CNY 1.11, up 105.56% from CNY 0.54 in the same period last year[21]. - The diluted earnings per share increased to CNY 0.99, representing an 83.33% increase compared to CNY 0.54 in the previous year[21]. - The weighted average return on equity rose to 8.21%, an increase of 3.52 percentage points from 4.69% in the same period last year[22]. - The company achieved consolidated revenue of CNY 1.643 billion, a year-on-year increase of 68.68%[39]. - Net profit attributable to shareholders reached CNY 199 million, reflecting a year-on-year growth of 105.44%[39]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 5,076,387,587.26, reflecting a 31.11% increase from CNY 3,871,812,905.97 at the end of the previous year[20]. - The net assets attributable to shareholders increased to CNY 2,506,822,046.18, a rise of 13.72% from CNY 2,204,468,089.72 at the end of the previous year[20]. - Total current assets increased to CNY 3,443,825,621.08 from CNY 2,406,656,060.81, representing a growth of approximately 43%[136]. - Total non-current assets reached CNY 1,632,561,966.18, compared to CNY 1,477,917,375.70, indicating an increase of about 10%[137]. - Total liabilities rose to CNY 1,857,771,955.71 from CNY 1,172,165,455.38, showing an increase of approximately 58%[138]. - The company's total assets amounted to CNY 5,076,387,587.26, up from CNY 3,884,573,436.51, representing a growth of about 30%[138]. Research and Development - Research and development expenses increased by 28.70% to CNY 69.74 million, driven by new projects and personnel growth[42]. - The company aims to strengthen its R&D capabilities and enhance its product offerings in the pesticide and fine chemical sectors[29]. - The company is focusing on enhancing its core competitiveness and R&D capabilities in response to national technology reform policies[41]. Market and Product Development - The company has seen a growing demand for its pesticide products due to increasing agricultural production needs and regulatory support[26]. - The overall market for pesticides is expected to grow, supported by government policies and increasing agricultural demands[26]. - The company is focusing on the production of pesticide products, including key products like Bacillus thuringiensis and pyraclostrobin, as well as flame retardants such as decabromodiphenyl ether[30]. - The company is actively pursuing market expansion and technological innovation to maintain its competitive edge[29]. Environmental Compliance and Sustainability - The company holds a pollution discharge permit and is classified as a key pollutant discharging unit, with specific emissions data reported[71]. - The company has implemented measures to ensure compliance with the emission standards set by the relevant environmental regulations[73]. - The company is focused on sustainable practices and environmental responsibility in its operations[76]. - The company has taken measures to reduce carbon emissions, including recycling steam condensate and implementing insulation on steam and hot water pipes to reduce energy loss[97]. Financial Management and Investments - The company completed a capital increase of RMB 205.2 million for its subsidiary Su Li Ningxia, raising its registered capital from RMB 300 million to RMB 430 million, maintaining a 76% ownership stake[49]. - The company issued RMB 957.21 million of convertible bonds, with a net fundraising amount of RMB 943.62 million after deducting issuance costs[124]. - The total amount of guarantees provided by the company, including those to subsidiaries, is RMB 821,000,000, which accounts for 25.51% of the company's net assets[115]. - The company plans to use cash flows from operating activities to repay the principal and interest of the convertible bonds in the future[133]. Risk Management - The company faced risks related to safety and environmental protection, emphasizing the need for compliance with increasingly stringent regulations[59]. - The company is facing risks from raw material price fluctuations, which significantly impact production and sales costs[61]. - The company has implemented measures to manage foreign exchange risks, including strengthening foreign exchange fund management and engaging in hedging activities[61]. Corporate Governance - The company has committed to fulfilling its obligations regarding performance compensation measures, with potential legal liabilities for any breaches[104]. - The company has not reported any violations or penalties against its directors, supervisors, or senior management during the reporting period[106]. - The company is focused on maintaining fair and reasonable pricing in its transactions with related parties[106]. Subsidiary Performance - The company’s subsidiary Su Li Chemical reported a net profit of RMB 2.59 million on revenue of RMB 31.71 million[58]. - The company’s subsidiary Bai Li Chemical achieved a net profit of RMB 21.71 million with revenue of RMB 133.44 million[58].

Financial Performance - The company's revenue for Q1 2022 reached ¥794,738,969.86, representing a 91.17% increase compared to the same period last year[6] - Net profit attributable to shareholders was ¥98,194,238.52, a significant increase of 158.48% year-on-year, primarily due to improved gross margins on product sales[6] - Basic earnings per share (EPS) increased by 161.90% to ¥0.55, while diluted EPS rose by 142.86% to ¥0.51[6] - Total operating revenue for Q1 2022 reached ¥794,738,969.86, a significant increase of 91.1% compared to ¥415,724,936.72 in Q1 2021[22] - Operating profit for Q1 2022 was ¥147,908,042.61, up 156.5% from ¥57,750,349.83 in the same period last year[23] - Net profit for Q1 2022 was ¥125,282,113.72, representing a 183.5% increase from ¥44,254,018.32 in Q1 2021[24] - Earnings per share for Q1 2022 were ¥0.55, compared to ¥0.21 in Q1 2021, reflecting a substantial growth[24] - The company reported a gross profit margin of approximately 18.9% for Q1 2022, compared to 13.5% in Q1 2021[22] - The total operating costs for Q1 2022 were ¥645,023,095.69, which is an increase of 81.0% from ¥356,305,364.10 in Q1 2021[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,819,476,288.77, reflecting a 24.48% increase from the previous year[6] - The company's total current assets as of March 31, 2022, amount to ¥3,320,270,006.20, an increase from ¥2,406,656,060.81 at the end of 2021[18] - Total assets reached ¥4,819,476,288.77, up from ¥3,871,812,905.97 in the previous year[19] - Total liabilities decreased to ¥1,693,539,362.40 from ¥1,853,540,948.74, reflecting a reduction of 8.6%[19] - Total liabilities as of Q1 2022 amounted to ¥1,707,105,162.30, compared to ¥1,172,165,455.38 in Q1 2021, indicating a growth of 45.5%[23] - Total equity increased to ¥3,112,371,126.47 in Q1 2022 from ¥2,699,647,450.59 in Q1 2021, marking a rise of 15.3%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥6,653,878.88, which is not applicable for year-on-year comparison[6] - Cash flow from operating activities for Q1 2022 was ¥6,653,878.88, a recovery from a negative cash flow of ¥84,746,621.86 in Q1 2021[27] - The net cash flow from investment activities was -343,127,430.89 CNY, compared to -98,556,670.72 CNY in the previous period, indicating a significant increase in cash outflow for investments[28] - The total cash inflow from financing activities amounted to 1,005,244,175.73 CNY, with a net cash flow of 945,900,072.85 CNY after outflows[28] - The cash and cash equivalents at the end of the period reached 1,586,113,955.49 CNY, up from 884,927,397.46 CNY in the previous period, reflecting a net increase of 608,701,006.95 CNY[28] - The company received 947,019,207.06 CNY from borrowings during the financing activities, contributing significantly to the cash inflow[28] - The cash outflow for investment activities totaled 358,077,745.38 CNY, which is a substantial increase compared to 129,435,736.72 CNY in the previous period[28] - The company reported an increase in cash received from minority shareholders' investments amounting to 58,224,968.67 CNY[28] - The impact of exchange rate changes on cash and cash equivalents was -725,513.89 CNY, indicating a slight negative effect[28] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 14,632[14] - The largest shareholder, Miao Jinfeng, holds 72,000,000 shares, representing 40.0% of total shares[15] - The number of shares held by the top ten shareholders accounts for a substantial portion of the company's equity, with the top shareholder alone holding 40%[15] Research and Development - Research and development expenses grew by 33.71%, attributed to increased investment in R&D projects and personnel[11] - Research and development expenses for Q1 2022 totaled ¥32,078,309.23, an increase of 33.8% from ¥23,990,655.01 in Q1 2021[23] Future Outlook - The company plans to continue expanding its product offerings and market presence, leveraging the increased demand and pricing power in its key product segments[11] - The company has not disclosed any significant new product developments or market expansion strategies in the current report[16]

Financial Performance - In 2021, the company's operating income reached approximately CNY 2.29 billion, representing a year-on-year increase of 47.03% compared to CNY 1.56 billion in 2020[21]. - The net profit attributable to shareholders was approximately CNY 232.39 million, an increase of 32.99% from CNY 174.75 million in the previous year[21]. - The cash flow from operating activities amounted to CNY 316.00 million, reflecting an 86.92% increase compared to CNY 169.06 million in 2020[21]. - The total assets of the company at the end of 2021 were approximately CNY 3.87 billion, a 26.19% increase from CNY 3.07 billion at the end of 2020[21]. - The company's net assets attributable to shareholders increased by 8.68% to approximately CNY 2.20 billion from CNY 2.03 billion in 2020[21]. - Basic earnings per share for 2021 were CNY 1.29, up 32.99% from CNY 0.97 in 2020[23]. - The weighted average return on equity was 11.01%, an increase of 2.26 percentage points from 8.75% in the previous year[23]. - The company achieved a historic breakthrough in consolidated operating revenue, indicating a stable recovery in profitability[32]. - The company achieved a consolidated revenue of 2.292 billion yuan, a year-on-year increase of 47.03%, and a net profit attributable to shareholders of 232 million yuan, up 32.99%[33]. Operational Highlights - In Q1 2021, the company's operating revenue was approximately ¥415.72 million, which increased to ¥715.72 million by Q4 2021, representing a growth of 72%[25]. - The net profit attributable to shareholders was ¥37.99 million in Q1 2021, rising to ¥93.12 million in Q4 2021, marking an increase of 145%[25]. - The cash flow from operating activities showed a significant recovery, moving from a negative ¥84.75 million in Q1 2021 to a positive ¥128.12 million in Q4 2021[25]. - The company achieved a consolidated revenue of CNY 2.292 billion, representing a year-on-year growth of 47.03%[46]. - The net profit attributable to shareholders reached CNY 232 million, marking a year-on-year increase of 32.99%[46]. Product and Market Development - The sales prices of key products such as pyraclostrobin, decabromodiphenyl ether, and hydrobromic acid maintained a growth trend in the second half of 2021, significantly contributing to revenue growth[33]. - The production of pyraclostrobin was stable, and the new production line for decabromodiphenyl ether operated well, leading to an increase in product output and sales volume[34]. - The revenue of the wholly-owned subsidiary, Suli Pharmaceutical, continued to grow, increasing by 32.99% compared to the same period last year[33]. - The company has completed the construction of a 15,000-ton decabromodiphenyl ether production line, which is expected to enhance profitability as it stabilizes operations[34]. - A new 5,000-ton brominated polystyrene production line has been completed and is ready for normal production, contributing to product structure improvement and market expansion[34]. Research and Development - The company is actively investing in R&D to enhance core competitiveness, with plans to build a more specialized R&D team and increase collaboration with academic institutions[34]. - The company has invested in R&D for new formulations and production technologies, particularly in the pesticide sector, to increase production capacity[43]. - The company received 11 invention patents during the reporting period, enhancing its innovation capabilities[87]. - The company emphasizes the importance of independent innovation, noting that firms with strong innovation capabilities will have better development opportunities[113]. Environmental Compliance and Sustainability - The company is committed to safety and environmental management, having obtained ISO14001 and OHSAS18001 certifications to ensure compliance with increasing regulatory standards[121]. - The company is focused on enhancing its production capabilities and expanding its market presence in the chemical industry[171]. - The company is actively monitoring and managing its environmental impact to align with regulatory requirements and sustainability goals[171]. - The company has implemented energy-saving measures, including the use of energy-efficient motors and automatic control of cooling systems, to reduce electricity consumption[195]. - The company has established an environmental self-monitoring plan for 2021, covering wastewater, waste gas, noise, and soil, with periodic monitoring conducted by qualified third parties[190]. Governance and Management - The company has established a governance structure compliant with regulations, ensuring independent operation of the board and effective decision-making[127]. - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements and effective governance[128]. - The company has a diverse board with members having extensive experience in various sectors, enhancing its strategic decision-making capabilities[135]. - The company’s governance structure includes independent directors who contribute to oversight and compliance, ensuring transparency in operations[135]. - The total remuneration for all directors, supervisors, and senior management was 7.2456 million yuan[142]. Employee Development and Welfare - In 2021, the company organized 433 training programs, achieving a completion rate of over 99%, reflecting a commitment to employee development[155]. - The company emphasizes safety and skill enhancement, with nearly 150 employees participating in safety training and skill improvement programs in 2021[154]. - The company has committed to protecting employee rights and has improved employee welfare, including timely payment of social insurance[196]. - The company has a diverse educational background among employees, with 5 holding PhDs and 28 holding master's degrees, enhancing its technical expertise[153]. Risk Management - The company faced challenges due to global supply chain shortages and inflationary pressures, which may impact future operations and profitability[31]. - The company is preparing for potential risks related to safety, environmental compliance, and supply chain disruptions due to ongoing pandemic-related challenges[122]. - The company is exposed to foreign exchange risks due to high overseas procurement and sales, with measures in place to manage currency fluctuations and mitigate financial risks[123]. - Ongoing capital investments in projects like the Ningxia project may lead to financial pressure and uncertain returns, prompting the company to improve investment management and efficiency[124].